Clinical Consequences of Withdrawing Guideline-Directed Medical Therapy in Heart Failure with Improved Ejection Fraction: A Systematic Review and Meta-Analysis.
Jul 2026· Critical Pathways in Cardiology· 0 citations
Medicine
TL;DR
A paradigm of continued, lifelong GDMT is mandated for vast majority of HFimpEF patients as they remain vulnerable despite apparent recovery, and continuation of GDMT is essential to prevent relapse and improve survival.
In patients with HFmrEF/HFpEF, there was no significant association between pharmacological BP lowering and clinical outcomes, suggesting that BP lowering alone is unlikely to explain all the benefits observed with the use of recently established HF therapies.
Samuel Jay-Jackson Pack, Sonia Sawant, C. Abhayaratna et al.· Heart· 0 citations
In HFpEF, beta-blocker discontinuation improved functional capacity and quality-of-life at 2 weeks compared with continuation with no clear effect on cognition, echocardiographic parameters or CV biomarkers, but findings on important long-term clinical outcomes was conflicting.
Wade Thompson, Nima Alaeiilkhchi, Lisa M. McCarthy et al.· Journal of Cardiac Failure· 0 citations
Guideline-directed medical therapy (GDMT) is crucial for the pharmacological management of heart failure (HF) with reduced ejection fraction (HFrEF). The aim of the study was to identify clinical characteristics associated with failure to achieve the prespecified stringent GDMT target in patients with HFrEF undergo...
A. Galas, R. Morawiec, I. Gorczyca-Głowacka et al.· Scientific Reports· 0 citations
Clinical evidence supporting the therapeutic benefits and safety of QSG in the management of hypertension with HFrEF may establish clinical evidence supporting the therapeutic benefits and safety of QSG in patients with hypertension and HFrEF.
Fu-Yuan Zhang, Zhao-Rui Cui, Zi-Rui Wang et al.· Frontiers in Cardiovascular...· 0 citations
Consistent improvements in LVEF, 6MWD and KCCQ-OSS across SGLT2i subgroups suggest that the observed benefits are independent of background pharmacologic intensification.
Marat Fudim, T. Kovačević-Preradović, D. Kosevic et al.· ESC Heart Failure· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.